Relay Therapeutics, Inc.
RLAY
Clasificación en acciones
#4032
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Precio por acción
$18.62
Capitalización bursátil
$4.08B
Cambio (1 día)
8.95%
Cambio (1 año)
160.77%
País
US
Comercio Relay Therapeutics, Inc. (RLAY)
Categoría
Healthcare
Número de acciones en circulación de Relay Therapeutics, Inc. (RLAY)
Número de acciones en circulación al June 2026: 202.85M
Según los últimos informes financieros y el precio de las acciones de Relay Therapeutics, Inc., el número actual de acciones en circulación es 202.85M. Al final de December 2023, la empresa tenía 122.58M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Relay Therapeutics, Inc. (RLAY) desde 2018 hasta 2026
Acciones en circulación al final de cada año
| Año | Acciones en circulación | Cambiar |
|---|---|---|
| 2026 (TTM) | 202.85M | 41.98% |
| 2024 | 142.87M | 16.55% |
| 2023 | 122.58M | 9.22% |
| 2022 | 112.23M | 17.97% |
| 2021 | 95.14M | 5.65% |
| 2020 | 90.05M | 2,003.45% |
| 2019 | 4.28M | 72.27% |
| 2018 | 2.49M | 0.00% |
Acciones en circulación de empresas similares o competidores
| Empresa | Acciones en circulación | Diferencia | País |
|---|---|---|---|
| 253.90M | 25.17% |
US
|
|
| 396.00M | 95.22% |
US
|
|
| 478.91M | 136.09% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -69.34% |
NL
|
